New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
08:03 EDTSLPSimulations Plus announces 'success' in COX-2, COX-1 drug design project
Simulations Plus announced that its second new chemical entity initiative, which involved using Simulations Plus software to design molecules to inhibit COX-2, has been a success as determined by synthesis and testing by a third-party lab. Three of the four molecules it has designed are potent inhibitors of both cyclooxygenase-2 and COX-1 enzymes. The fourth inhibits COX-2 but only weakly inhibits COX-1. The company said, "This project was more challenging than the malaria NCE project we completed two years ago because this time our goal was to inhibit two targets with a single molecule while also providing good absorption, distribution, metabolism, excretion, and toxicity properties."
News For SLP From The Last 14 Days
Check below for free stories on SLP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
08:04 EDTSLPSimulations Plus wins cooperative agreement with FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use